Technical Analysis for ARGX - argenx SE
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 277.96 | -1.09% | -3.07 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Flat |
| Historical ARGX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | -1.09% | |
| Narrow Range Bar | Range Contraction | -1.09% | |
| NR7 | Range Contraction | -1.09% | |
| NR7-2 | Range Contraction | -1.09% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| 200 DMA Support | about 21 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/04/2021
argenx SE Description
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Inflammation Lymphoma Cancer Immunotherapy Autoimmune Disease Acute Myeloid Leukemia Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Dyslipidemia Hematological Cancers Myasthenia Myasthenia Gravis Thrombocytopenia Janus Kinase Inhibitor Rgx Skin Inflammation Tolerx Treatment Of Hematological Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 382.15 |
| 52 Week Low | 130.0 |
| Average Volume | 211,381 |
| 200-Day Moving Average | 275.39 |
| 50-Day Moving Average | 320.19 |
| 20-Day Moving Average | 291.91 |
| 10-Day Moving Average | 279.08 |
| Average True Range | 10.26 |
| ADX | 29.85 |
| +DI | 17.26 |
| -DI | 31.61 |
| Chandelier Exit (Long, 3 ATRs ) | 290.43 |
| Chandelier Exit (Short, 3 ATRs ) | 299.45 |
| Upper Bollinger Band | 322.39 |
| Lower Bollinger Band | 261.43 |
| Percent B (%b) | 0.27 |
| BandWidth | 20.88 |
| MACD Line | -10.99 |
| MACD Signal Line | -11.29 |
| MACD Histogram | 0.3007 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 284.67 | ||||
| Resistance 3 (R3) | 284.35 | 281.81 | 283.55 | ||
| Resistance 2 (R2) | 281.81 | 280.10 | 281.96 | 283.17 | |
| Resistance 1 (R1) | 279.88 | 279.04 | 280.85 | 280.20 | 282.80 |
| Pivot Point | 277.34 | 277.34 | 277.82 | 277.49 | 277.34 |
| Support 1 (S1) | 275.41 | 275.63 | 276.38 | 275.73 | 273.12 |
| Support 2 (S2) | 272.87 | 274.57 | 273.02 | 272.75 | |
| Support 3 (S3) | 270.94 | 272.87 | 272.37 | ||
| Support 4 (S4) | 271.26 |
